Geir Erland Tjønnfjord

• Hamnvik, Lars Henrik Dahl; Tjønnfjord, Geir Erland; Spetalen, Signe & Dalgaard, Jakob (2024). Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report. Journal of Medical Case Reports. ISSN 1752-1947. 18(1). doi: 10.1186/s13256-024-04562-8.
• Podgorica, Mirjam; Drivet, Elsa Maria Caroline; Viken, Jonas Krag; Richman, Alyssa; Vestbøstad, Johanne Bonsaksen & Szodoray, Peter [Show all 12 contributors for this article] (2024). Transcriptome analysis of primary adult B-cell lineage acute lymphoblastic leukemia identifies pathogenic variants and gene fusions, and predicts subtypes for in depth molecular diagnosis. European Journal of Haematology. ISSN 0902-4441. doi: 10.1111/ejh.14164.
• Malecka, Agnieszka Maria; Østlie, Ingunn; Trøen, Gunhild; Malecki, Jedrzej Mieczyslaw; Delabie, Jan & Tierens, Anne [Show all 9 contributors for this article] (2023). Gene expression analysis revealed downregulation of complement receptor 1 in clonal B cells in cold agglutinin disease. Clinical and Experimental Immunology. ISSN 0009-9104. 216(1), p. 45–54. doi: 10.1093/cei/uxad135. Full text in Research Archive
• Måseide, Ragnhild Johanne; Berntorp, Erik; Astermark, Jan; Olsson, Anna; Bruzelius, Maria & Frisk, Tony [Show all 10 contributors for this article] (2023). Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study). Haemophilia. ISSN 1351-8216. doi: 10.1111/hae.14899.
• Hillarp, Andreas; Holme, Pål Andre; Wåland, Erik Pareli; Skogstad, Marie Jeanette; Henriksson, Carola Elisabeth & Tjønnfjord, Geir Erland [Show all 7 contributors for this article] (2023). Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 21(10), p. 2771–2775. doi: 10.1016/j.jtha.2023.07.019. Full text in Research Archive
• Ali, Maryan Mohamed; Gedde-Dahl, Tobias; Osnes, Liv T. N.; Perrier, Flavie; Veierød, Marit Bragelien & Tjønnfjord, Geir Erland [Show all 7 contributors for this article] (2023). Extracorporeal Photopheresis as Graft-versus-Host Disease Prophylaxis: A Randomized Controlled Trial. Transplantation and Cellular Therapy (TCT). ISSN 2666-6375. 29(6), p. 364.e1–364.e11. doi: 10.1016/j.jtct.2023.02.023. Full text in Research Archive
• Hermansen, Johanne Uthus; Yin, Yanping; Urban, Aleksandra; Myklebust, Camilla Victoria; Karlsen, Linda & Melvold, Katrine [Show all 11 contributors for this article] (2023). A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine. Cell death discovery. ISSN 2058-7716. 9. doi: 10.1038/s41420-023-01426-w. Full text in Research Archive
• Vo, Camilla Dao; Myhre, Anders Eivind; Abrahamsen, Ingerid Weum; Remberger, Mats; Mattsson, Jonas & Fløisand, Yngvar [Show all 10 contributors for this article] (2023). Allogen stamcelletransplantasjon hos voksne 2015–21. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(4). doi: 10.4045/tidsskr.22.0521. Full text in Research Archive
• Gudmundstuen, Anne Marte; Efficace, Fabio; Tjønnfjord, Geir Erland; Skaarud, Kristin Aneta Joan; Cottone, Francesco & Hjermstad, Marianne Jensen [Show all 7 contributors for this article] (2023). The prognostic value of patient-reported outcomes in allogeneic hematopoietic stem cell transplantation: exploratory analysis of a randomized nutrition intervention trial. Annals of Hematology. ISSN 0939-5555. 102(4), p. 927–935. doi: 10.1007/s00277-023-05149-x. Full text in Research Archive Show summary

  Whether patient-reported outcomes (PROs) can predict overall survival (OS) and non-relapse mortality (NRM) among recipients of allogeneic stem cell transplantation (allo-HSCT), is unclear. We performed an exploratory analysis of the prognostic value of patient-reported outcomes (PROs) among 117 recipients of allogeneic stem cell transplantation (allo-HSCT) who participated in a randomized nutrition intervention trial. Cox proportional hazards models were used to investigate possible associations between PROs collected pre-allo-HSCT (baseline) using scores from the EORTC Quality of Life Questionnaire-Core 30 (QLQ-C30) and 1-year overall survival (OS), whereas logistic regression was used to study associations between these PROs and 1-year non-relapse mortality (NRM). Multivariable analyses indicated that only the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) and the European Bone Marrow Transplantation (EBMT) risk score were associated with 1-year OS. In the multivariable model including clinical-sociodemographic factors for 1-year NRM, our analysis showed that living alone (p=0.009), HCT-CI (p=0.016), EBMT risk score (p=0.002), and stem cell source (p=0.046) could be associated with 1-year NRM. Moreover, in the multivariable model, our analysis showed that only appetite loss from the QLQ-C30 was associated with 1-year NRM (p=0.026). In conclusion, in this specific setting, our analysis suggests that the commonly used HCT-CI and EBMT risk scores could be predictive for both 1-year OS and 1-year NRM, whereas baseline PROs in general were not.

• Diep, Phoi Phoi; Rüegg, Corina Silvia; Dirdal, Marta Maria; Brinch, Lorentz; BØ, KRISTINE & Fosså, Kristian [Show all 17 contributors for this article] (2022). Graft-Versus-Host-Disease and Health-Related Quality of Life in Young Long-term Survivors of Cancer and Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Adolescent and Young Adult Oncology. ISSN 2156-5333. 12(1), p. 66–75. doi: 10.1089/jayao.2021.0196.
• Yin, Yanping; Athanasiadis, Paschalis; Karlsen, Linda; Urban, Aleksandra; Xu, Haifeng & Murali, Ishwarya [Show all 17 contributors for this article] (2022). Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia. Clinical Cancer Research. ISSN 1078-0432. 28(20), p. 4444–4455. doi: 10.1158/1078-0432.CCR-22-1221. Full text in Research Archive Show summary

  Purpose: PI3K inhibitors (PI3Ki) are approved for relapsed chronic lymphocytic leukemia (CLL). Although patients may show an initial response to these therapies, development of treatment intolerance or resistance remain clinical challenges. To overcome these, prediction of individual treatment responses based on actionable biomarkers is needed. Here, we characterized the activity and cellular effects of 10 PI3Ki and investigated whether functional analyses can identify treatment vulnerabilities in PI3Ki-refractory/intolerant CLL and stratify responders to PI3Ki. Experimental Design: Peripheral blood mononuclear cell samples (n = 51 in total) from treatment-naïve and PI3Ki-treated patients with CLL were studied. Cells were profiled against 10 PI3Ki and the Bcl-2 antagonist venetoclax. Cell signaling and immune phenotypes were analyzed by flow cytometry. Cell viability was monitored by detection of cleaved caspase-3 and the CellTiter-Glo assay. Results: pan-PI3Kis were most effective at inhibiting PI3K signaling and cell viability, and showed activity in CLL cells from both treatment-naïve and idelalisib-refractory/intolerant patients. CLL cells from idelalisib-refractory/intolerant patients showed overall reduced protein phosphorylation levels. The pan-PI3Ki copanlisib, but not the p110δ inhibitor idelalisib, inhibited PI3K signaling in CD4+ and CD8+ T cells in addition to CD19+ B cells, but did not significantly affect T-cell numbers. Combination treatment with a PI3Ki and venetoclax resulted in synergistic induction of apoptosis. Analysis of drug sensitivities to 73 drug combinations and profiling of 31 proteins stratified responders to idelalisib and umbralisib, respectively. Conclusions: Our findings suggest novel treatment vulnerabilities in idelalisib-refractory/intolerant CLL, and indicate that ex vivo functional profiling may stratify PI3Ki responders.

• Haroun-Izquierdo, Alvaro; Vincenti, Marianna; Netskar, Herman Krogstad; van Ooijen, Hanna; Zhang, Bin & Bendzick, Laura [Show all 30 contributors for this article] (2022). Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia. Journal for ImmunoTherapy of Cancer (JITC). 10:e005577(11), p. 1–13. doi: 10.1136/jitc-2022-005577. Full text in Research Archive
• Berentsen, Sigbjørn & Tjønnfjord, Geir Erland (2022). Current Treatment Options in Cold Agglutinin Disease: B-Cell Directed or Complement Directed Therapy? Transfusion Medicine Reviews. ISSN 0887-7963. 36(4), p. 181–187. doi: 10.1016/j.tmrv.2022.05.001. Full text in Research Archive
• Skånland, Sigrid S & Tjønnfjord, Geir Erland (2022). Determining drug dose in the era of targeted therapies: playing it (un)safe? Blood Cancer Journal. ISSN 2044-5385. 12(8). doi: 10.1038/s41408-022-00720-7. Full text in Research Archive
• Skånland, Sigrid S; Inngjerdingen, Marit; Bendiksen, Henrik; York, Jamie Piers; Spetalen, Signe & Munthe, Ludvig Andre [Show all 7 contributors for this article] (2022). Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case. Haematologica. ISSN 0390-6078. 107(8), p. 1994–1998. doi: 10.3324/haematol.2021.280393. Full text in Research Archive
• Imbery, John Franklin; Heinzelbecker, Julia; Jebsen, Jenny Karoline; McGowan, Marc Kevin; Myklebust, Camilla Victoria & Bottini, Nunzio [Show all 13 contributors for this article] (2022). T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation. British Journal of Haematology. ISSN 0007-1048. 198(3), p. 556–573. doi: 10.1111/bjh.18285. Full text in Research Archive
• Solhaug, Terje Singsaas; Tjønnfjord, Geir Erland; BJØRGO, KATHRINE & Kildahl-Andersen, Odd A (2022). A family with cytotoxic T-lymphocyte-associated protein 4 haploinsufficiency presenting with aplastic anaemia. BMJ Case Reports. ISSN 1757-790X. 15(2). doi: 10.1136/bcr-2021-247653.
• Jønsson, Viggo; Awan, Haneef; Jones, Neil Deaton; Johannessen, Tom Børge; Thøgersen, Klaus & Steig, Bjarni á [Show all 8 contributors for this article] (2022). Meiotic drive in chronic lymphocytic leukemia compared with other malignant blood disorders. Scientific Reports. ISSN 2045-2322. 12:6138(1), p. 1–11. doi: 10.1038/s41598-022-09602-1. Full text in Research Archive
• Giliberto, Mariaserena; Thimiri Govinda Raj, Deepak Balaji; Cremaschi, Andrea; Skånland, Sigrid S; Gade, Alexandra & Tjønnfjord, Geir Erland [Show all 9 contributors for this article] (2022). Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically. Molecular Oncology. ISSN 1574-7891. 16(6), p. 1241–1258. doi: 10.1002/1878-0261.13191. Full text in Research Archive Show summary

  The management of multiple myeloma (MM) is challenging: An assortment of available drug combinations adds complexity to treatment selection, and treatment resistance frequently develops. Given the heterogeneous nature of MM, personalized testing tools are required to identify drug sensitivities. To identify drug sensitivities in MM cells, we established a drug testing pipeline to examine ex vivo drug responses. MM cells from 44 patients were screened against 30 clinically relevant single agents and 44 double- and triple-drug combinations. We observed variability in responses across samples. The presence of gain(1q21) was associated with low sensitivity to venetoclax, and decreased ex vivo responses to dexamethasone reflected the drug resistance observed in patients. Less heterogeneity and higher efficacy was detected with many combinations compared to the corresponding single agents. We identified new synergistic effects of melflufen plus panobinostat using low concentrations (0.1–10 nm and 8 nm, respectively). In agreement with clinical studies, clinically approved combinations, such as triple combination of selinexor plus bortezomib plus dexamethasone, acted synergistically, and synergies required low drug concentrations (0.1 nm bortezomib, 10 nm selinexor and 4 nm dexamethasone). In summary, our drug screening provided results within a clinically actionable 5-day time frame and identified synergistic drug efficacies in patient-derived MM cells that may aid future therapy choices.

• Vojdeman, Fie J.; Pedersen, Lone B.; Te Raa, Doreen; Juvonen, Vesa; van Norden, Yvette & Tjønnfjord, Geir Erland [Show all 17 contributors for this article] (2021). B-cell receptor stereotyped subsets and outcome for patients with chronic lymphocytic leukemia in the HOVON 68 trial. Journal of translational genetics and genomics. ISSN 2578-5281. 2021(5), p. 182–188. doi: 10.20517/jtgg.2021.03.
• Remberger, Mats; Tjønnfjord, Geir Erland; Abrahamsen, Ingerid Weum; Ali, Maryan Mohamed; Myhre, Anders Eivind & Gedde-Dahl, Tobias [Show all 7 contributors for this article] (2021). Superior Graft-versus-Host Disease-Free Relapse-Free Survival in Matched Unrelated Donor Hematopoietic Stem Cell Transplantation with Anti-Thymocyte Globulin (ATG) Compared to Matched Related Donor without ATG. Transplantation and Cellular Therapy (TCT). ISSN 2666-6375. 27(7), p. 621.e1–621.e3. doi: 10.1016/j.jtct.2021.03.019.
• Ali, Maryan Mohamed; Grønvold, Bjørn Christer Linder; Remberger, Mats; Abrahamsen, Ingerid Weum; Myhre, Anders Eivind & Tjønnfjord, Geir Erland [Show all 8 contributors for this article] (2021). Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival. Clinical Lymphoma, Myeloma & Leukemia. ISSN 2152-2650. 21(9), p. 598–605. doi: 10.1016/j.clml.2021.05.003. Full text in Research Archive
• Ali, Muhammad; Giannakopoulou, Eirini Chrysovalantou; Li, Yingqian; Lehander, Madeleine; Virding Culleton, Stina & Yang, Weiwen [Show all 33 contributors for this article] (2021). T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nature Biotechnology. ISSN 1087-0156. doi: 10.1038/s41587-021-01089-x. Full text in Research Archive
• Melvold, Katrine; Giliberto, Mariaserena; Karlsen, Linda; Ayuda-Duran, Maria del Pilar; Hanes, Robert & Holien, Toril [Show all 11 contributors for this article] (2021). Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies. Molecular Oncology. ISSN 1574-7891. p. 1–18. doi: 10.1002/1878-0261.13153. Full text in Research Archive Show summary

  Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we performed direct drug testing on primary CLL cells and identified synergy between eight different mitogen-activated protein kinase kinase (MEK) inhibitors and the B-cell lymphoma 2 (Bcl-2) antagonist venetoclax. Drug sensitivity was independent of immunoglobulin heavy-chain gene variable region (IGVH) and tumor protein p53 (TP53) mutational status, and CLL cells from idelalisib-resistant patients remained sensitive to the treatment. This suggests that combined MEK/Bcl-2 inhibition may be an option for high-risk CLL. To test whether sensitivity could be detected in other B-cell malignancies, we performed drug testing on cell line models of CLL (n = 4), multiple myeloma (MM; n = 8), and mantle cell lymphoma (MCL; n = 7). Like CLL, MM cells were sensitive to the MEK inhibitor trametinib, and synergy was observed with venetoclax. In contrast, MCL cells were unresponsive to MEK inhibition. To investigate the underlying mechanisms of the disease-specific drug sensitivities, we performed flow cytometry-based high-throughput profiling of 31 signaling proteins and regulators of apoptosis in the 19 cell lines. We found that high expression of the antiapoptotic proteins myeloid cell leukemia-1 (Mcl-1) or B-cell lymphoma-extra large (Bcl-xL) predicted low sensitivity to trametinib + venetoclax. The low sensitivity could be overcome by combined treatment with an Mcl-1 or Bcl-xL inhibitor. Our findings suggest that MEK/Bcl-2 inhibition has therapeutic potential in leukemia and myeloma, and demonstrate that protein expression levels can serve as predictive biomarkers for treatment sensitivities.

• Tjønnfjord, Geir Erland; Schjesvold, Fredrik Hellem; Gulbrandsen, Nina & Kvam, Ann Kristin (2021). Monoklonal gammopati av klinisk betydning. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 141(13), p. 1–9. doi: 10.4045/tidsskr.20.0981. Full text in Research Archive
• Måseide, Ragnhild Johanne; Berntorp, Erik; Nummi, Vuokko; Lassila, Riitta; Tjønnfjord, Geir E. & Holme, Pål A. (2021). Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation. Haemophilia. ISSN 1351-8216. p. 1–10. doi: 10.1111/hae.14355. Full text in Research Archive
• Cui, Xueyan; Tjønnfjord, Geir Erland; Kanse, Sandip; Dahm, Anders Erik A; Iversen, Nina & Myklebust, Christiane Filion [Show all 12 contributors for this article] (2021). Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. Scientific Reports. ISSN 2045-2322. 11. doi: 10.1038/s41598-021-84695-8. Full text in Research Archive
• Schultz, Nina Haagenrud; Sørvoll, Ingvild Hausberg; Michelsen, Annika; Munthe, Ludvig Andre; Lund-Johansen, Fridtjof & Ahlen, Maria Therese [Show all 11 contributors for this article] (2021). Thrombosis and thrombocytopenia after CHADOX1 NCoV-19 vaccination. New England Journal of Medicine. ISSN 0028-4793. 384(22), p. 2124–2130. doi: 10.1056/NEJMoa2104882. Full text in Research Archive
• Skaarud, Kristin Aneta Joan; Hov, Johannes Espolin Roksund; Hansen, Simen Hyll; Kummen, Martin; Valeur, Jørgen & Seljeflot, Ingebjørg [Show all 12 contributors for this article] (2021). Mortality and microbial diversity after allogenic hematopoietic stem cell transplantation: secondary analysis of a randomized nutritional intervention trial. Scientific Reports. ISSN 2045-2322. doi: 10.1038/s41598-021-90976-z. Full text in Research Archive
• Måseide, Ragnhild Johanne; Berntorp, Erik; Astermark, Jan; Hansen, Jessica; Olsson, Anna & Bruzelius, Maria [Show all 11 contributors for this article] (2021). Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study. Haemophilia. ISSN 1351-8216. 27(2), p. e253–e259. doi: 10.1111/hae.14245. Full text in Research Archive
• Mirlashari, Mohammad Reza; Vetlesen, Annette; Nissen-Meyer, Lise Sofie Haug; Naper, Christian; Tjønnfjord, Geir Erland & Unhammer Njerve, Ida [Show all 12 contributors for this article] (2021). HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients. Transfusion. ISSN 0041-1132. 61(4), p. 1222–1234. doi: 10.1111/trf.16282. Full text in Research Archive
• Lenartova, Andrea; Johannessen, Tom Børge & Tjønnfjord, Geir Erland (2020). Chronic lymphocytic leukemia and secondary hematological malignancies: A nation-wide cancer registry study. European Journal of Haematology. ISSN 0902-4441. 104(6), p. 546–553. doi: 10.1111/ejh.13396. Full text in Research Archive
• Marvyin, Kristo; Tjønnfjord, Eirik; Breland, Unni Mathilde & Tjønnfjord, Geir Erland (2020). Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment. BMJ Case Reports. ISSN 1757-790X. 13:e235816(9), p. 1–3. doi: 10.1136/bcr-2020-235816.
• Berentsen, Sigbjørn; Malecka, Agnieszka Maria; Randen, Ulla & Tjønnfjord, Geir Erland (2020). Cold agglutinin disease: where do we stand, and where are we going? Clinical Advances in Hematology & Oncology (CAH&O). ISSN 1543-0790. 18(1), p. 35–44.
• Berentsen, Sigbjørn; Barcellini, Wilma; D'Sa, Shirley; Randen, Ulla; Tvedt, Tor Henrik Anderson & Fattizzo, Bruno [Show all 23 contributors for this article] (2020). Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. ISSN 0006-4971. 136(4), p. 480–488. doi: 10.1182/blood.2020005674.
• Måseide, Ragnhild Johanne; Berntorp, Erik; Astermark, Jan; Olsson, Anna; Bruzelius, Maria & Frisk, Tony [Show all 10 contributors for this article] (2020). Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study. Haemophilia. ISSN 1351-8216. 26(5), p. 891–897. doi: 10.1111/hae.14114. Full text in Research Archive
• Hetland, Geir; Tangen, Jon-Magnus; Mahmood, Faiza; Mirlashari, Mohammad Reza; Nissen-Meyer, Lise Sofie Haug & Nentwich, Ivo [Show all 9 contributors for this article] (2020). Antitumor, Anti-inflammatory and Antiallergic Effects of Agaricus blazei Mushroom Extract and the Related Medicinal Basidiomycetes Mushrooms, Hericium erinaceus and Grifola frondosa: A Review of Preclinical and Clinical Studies . Nutrients. ISSN 2072-6643. 12(5), p. 1–19. doi: 10.3390/nu12051339.
• Mpinganzima, Clarisse; Haaland, Alf; Holm, Anne Guro Vreim; Thein, Swee Lay; Tjønnfjord, Geir Erland & Iversen, Per Ole (2020). Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient. Case Reports in Hematology. ISSN 2090-6560. doi: 10.1155/2020/2765012. Full text in Research Archive
• Tvedt, Tor Henrik Anderson; Skaarud, Kristin Aneta Joan; Tjønnfjord, Geir Erland; Gedde-Dahl, Tobias; Iversen, Per Ole & Bruserud, Øystein (2020). The systemic metabolic profile early after allogeneic stem cell transplantation: Effects of adequate energy support administered through enteral feeding tube. Biology of Blood and Marrow Transplantation. ISSN 1083-8791. 26(2), p. 380–391. doi: 10.1016/j.bbmt.2019.10.005.
• Yaddehi Gamage, Thilini Hansamali Gamage; Lengle, Emma; Gunnes, Gjermund; Pullisaar, Helen; Holmgren, Asbjørn & Reseland, Janne Elin [Show all 16 contributors for this article] (2019). STIM1 R304W in mice causes subgingival hair growth and an increased fraction of trabecular bone. Cell Calcium. ISSN 0143-4160. 85. doi: 10.1016/j.ceca.2019.102110.
• Skånland, Sigrid Strand; Cremaschi, Andrea; Bendiksen, Henrik; Hermansen, Johanne Uthus; Thimiri Govinda Raj, Deepak Balaji & Munthe, Ludvig Andre [Show all 8 contributors for this article] (2019). An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL. Leukemia. ISSN 0887-6924. doi: 10.1038/s41375-019-0569-7.
• Berentsen, Sigbjørn; Roth, Alexandra; Randen, Ulla; Jilma, Bernd & Tjønnfjord, Geir Erland (2019). Cold agglutinin disease: Current challenges and future prospects. Journal of Blood Medicine. ISSN 1179-2736. 10, p. 93–103. doi: 10.2147/JBM.S177621. Full text in Research Archive
• Skaarud, Kristin Aneta Joan; Veierød, Marit Bragelien; Lergenmuller, Simon; Bye, Asta; Iversen, Per Ole & Tjønnfjord, Geir Erland (2019). Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients . Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-019-0638-6. Full text in Research Archive
• Lenartova, Andrea; Randen, Ulla; Johannessen, Tom Børge & Tjønnfjord, Geir Erland (2019). Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway. Cancer Epidemiology. ISSN 1877-7821. 60, p. 128–133. doi: 10.1016/j.canep.2019.04.002.
• Torkildsen, Synne; Gorunova, Ludmila; Heim, Sverre; Tjønnfjord, Geir Erland; Spetalen, Signe & Risberg, Bente [Show all 8 contributors for this article] (2019). Molecular Genetic Characterization of Acute Myeloid Leukemia With Trisomy 4 as the Sole Chromosome Abnormality. Cancer Genomics & Proteomics. ISSN 1109-6535. 16(3), p. 175–178. doi: 10.21873/cgp.20123. Full text in Research Archive
• Andersen, May-Linn Fauske; Holme, Pål Andre & Tjønnfjord, Geir Erland (2019). Surgical intervention in patients with severe bleeding disorder 1997-2014. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 139(8), p. 709–712. doi: 10.4045/tidsskr.18.0592. Show summary

  BACKGROUND As a result of good medical treatment, the life expectancy of patients with severe haemophilia is now approaching normal. This implies a growing need for treatment of lifestyle- and age-related disease. This article describes surgery in patients with severe haemophilia in the period 1997–2014. MATERIAL AND METHOD Data were retrieved from the registry linked to the national treatment service for surgery, intervention and advanced diagnostics for haemophilia. The patients were categorised according to type of haemophilia and type of intervention in orthopaedic and non-orthopaedic surgical procedures. RESULTS A total of 825 surgical procedures were undertaken in 286 patients. The number of procedures increased from 21 in 1997 to 66 in 2014. This increase was associated with non-orthopaedic interventions: altogether 4 such procedures were undertaken in 1997 and 45 in 2014. The number of orthopaedic interventions varied somewhat from year to year, but no clear trend was evident. INTERPRETATION With increased life expectancy, we are seeing a growing need for treatment of diseases that are not causally related to haemophilia. Doctors with little experience of patients with severe haemophilia will need to deal with lifestyle- and age-related disease in this patient group.

• Chellappa, Stalin ; Kushekhar, Kushi; Munthe, Ludvig Andre; Tjønnfjord, Geir Erland; Aandahl, Einar Martin & Okkenhaug, Klaus [Show all 7 contributors for this article] (2019). The PI3K p110δ isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function. Journal of Immunology. ISSN 0022-1767. 202(5), p. 1397–1405. doi: 10.4049/jimmunol.1701703.
• Jønsson, Viggo; Awan, Haneef; Jones, Neil D.; Johannessen, Tom Børge; Steig, Bjarni A & Andosdottir, Gudrid [Show all 7 contributors for this article] (2019). Inheritance of Susceptibility to Malignant Blood Disorders. Scientific Reports. ISSN 2045-2322. 9, p. 1–12. doi: 10.1038/s41598-019-38879-y. Full text in Research Archive
• Hermansen, Johanne Uthus; Tjønnfjord, Geir Erland; Munthe, Ludvig Andre; Tasken, Kjetil & Skånland, Sigrid Strand (2018). Cryopreservation of primary B cells minimally influences their signaling responses. Scientific Reports. ISSN 2045-2322. 8:17651, p. 1–7. doi: 10.1038/s41598-018-36121-9. Full text in Research Archive
• Yaddehi Gamage, Thilini Hansamali Gamage; Gunnes, Gjermund; Lee, Robert Hugh; Louch, William Edward; Holmgren, Asbjørn & Bruton, Joseph D. [Show all 19 contributors for this article] (2018). STIM1 R304W causes muscle degeneration and impaired platelet activation in mice. Cell Calcium. ISSN 0143-4160. 76, p. 87–100. doi: 10.1016/j.ceca.2018.10.001. Full text in Research Archive Show summary

  STIM1 and ORAI1 regulate store-operated Ca2+ entry (SOCE) in most cell types, and mutations in these proteins have deleterious and diverse effects. We established a mouse line expressing the STIM1 R304 W gain-of-function mutation causing Stormorken syndrome to explore effects on organ and cell physiology. While STIM1 R304 W was lethal in the homozygous state, surviving mice presented with reduced growth, skeletal muscle degeneration, and reduced exercise endurance. Variable STIM1 expression levels between tissues directly impacted cellular SOCE capacity. In contrast to patients with Stormorken syndrome, STIM1 was downregulated in fibroblasts from Stim1R304W/R304W mice, which maintained SOCE despite constitutive protein activity. In studies using foetal liver chimeras, STIM1 protein was undetectable in homozygous megakaryocytes and platelets, resulting in impaired platelet activation and absent SOCE. These data indicate that downregulation of STIM1 R304 W effectively opposes the gain-of-function phenotype associated with this mutation, and highlight the importance of STIM1 in skeletal muscle development and integrity.

• Holme, Pål Andre & Tjønnfjord, Geir Erland (2018). Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries. Haemophilia. ISSN 1351-8216. p. 1–6. doi: 10.1111/hae.13625. Full text in Research Archive
• Tangen, Jon-Magnus; Tjønnfjord, Geir Erland; Gulbrandsen, Nina; Gedde-Dahl, Thobias; Stormorken, Espen & Anderson, Kristina [Show all 9 contributors for this article] (2018). Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: A retrospective, population based analysis. BMC Cancer. ISSN 1471-2407. 18:801, p. 1–9. doi: 10.1186/s12885-018-4722-x. Full text in Research Archive
• Jagjit, Bhamra Singh; Iversen, Per Ole; Tjønnfjord, Geir Erland; Akkøk, Cigdem Ahaein & Titze, Thomas Larsen (2018). A case of post-transfusion purpura with severe refractory thrombocytopenia but no cutaneous manifestations. Case Reports in Hematology. ISSN 2090-6560. doi: 10.1155/2018/8187659. Full text in Research Archive
• Skaarud, Kristin Aneta Joan; Hjermstad, Marianne Jensen; Bye, Asta; Veierød, Marit Bragelien; Gudmundstuen, Anne Marte & Lundin, Knut Erik Aslaksen [Show all 10 contributors for this article] (2018). Effects of individualized nutrition after allogeneic hematopoietic stem cell transplantation following myeloablative conditioning; a randomized controlled trial. Clinical Nutrition ESPEN. ISSN 2405-4577. 28, p. 59–66. doi: 10.1016/j.clnesp.2018.08.002.
• Rogne, Marie; Svärd, Oksana; Madsen-Østerbye, Julia-Kristina Jensen; Hashim, Adnan; Tjønnfjord, Geir Erland & Staerk, Judith (2018). Cytokinesis arrest and multiple centrosomes in B cell chronic lymphocytic leukaemia. Journal of Cellular and Molecular Medicine. ISSN 1582-1838. 22(5), p. 2846–2855. doi: 10.1111/jcmm.13579. Full text in Research Archive
• Myhrvold, Ida Kristin; Cremaschi, Andrea; Hermansen, Johanne Uthus; Tjønnfjord, Geir Erland; Munthe, Ludvig Andre & Tasken, Kjetil [Show all 7 contributors for this article] (2018). Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia. OncoTarget. ISSN 1949-2553. 9(10), p. 9273–9284. doi: 10.18632/oncotarget.23949. Full text in Research Archive
• Habberstad, Andreas Hanssønn; Tran, Hoa Thi Tuyet; Randen, Ulla; Spetalen, Signe; Dybedal, Ingunn & Tjønnfjord, Geir Erland [Show all 7 contributors for this article] (2018). Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: A case report. Journal of Medical Case Reports. ISSN 1752-1947. 12(1). doi: 10.1186/s13256-018-1663-6. Full text in Research Archive
• Panagopoulos, Ioannis; Gorunova, Ludmila; Torkildsen, Synne; Tjønnfjord, Geir Erland; Micci, Francesca & Heim, Sverre (2017). DEK-NUP214-fusion identified by RNA-sequencing of an acute myeloid leukemia with t(9;12)(q34;q15). Cancer Genomics & Proteomics. ISSN 1109-6535. 14(6), p. 437–443. doi: 10.21873/CGP.20053.
• Holme, Pål Andre; Tjønnfjord, Geir Erland & Batorova, A (2017). Continuous infusion of coagulation factor concentrates during intensive treatment. Haemophilia. ISSN 1351-8216. 24(1), p. 24–32. doi: 10.1111/hae.13331.
• Malecka, Agnieszka Maria; Trøen, Gunhild; Tierens, Anne; Østlie, Ingunn; Malecki, Jedrzej Mieczyslaw & Randen, Ulla [Show all 10 contributors for this article] (2017). Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. British Journal of Haematology. ISSN 0007-1048. 183(5), p. 838–842. doi: 10.1111/bjh.15063.
• Tjønnfjord, Eirik; Vengen, Øystein; Berentsen, Sigbjørn & Tjønnfjord, Geir Erland (2017). Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease. BMJ Case Reports. ISSN 1757-790X. 2017, p. 1–4. doi: 10.1136/bcr-2016-219066.
• Wang, Dong; Fløisand, Yngvar; Myklebust, Camilla Victoria; Bürgler, Simone; Ribes, Anna Maria Parente & Hofgaard, Peter Olaf [Show all 13 contributors for this article] (2017). Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice. Leukemia. ISSN 0887-6924. 31(10), p. 2114–2121. doi: 10.1038/leu.2017.69. Full text in Research Archive
• Berentsen, Sigbjørn; Randen, Ulla; Oksman, Markku; Birgens, Henrik; Tvedt, Tor Henrik Anderson & Dalgaard, Jakob [Show all 13 contributors for this article] (2017). Bendamustine plus rituximab for chronic cold agglutinin disease: Results of a Nordic prospective multicenter trial. Blood. ISSN 0006-4971. 130(4), p. 537–541. doi: 10.1182/blood-2017-04-778175.
• Vojdeman, Fie Juhl; Herman, Sarah E.M.; Kirkby, Nikolai; Wiestner, Adrian; van t' Veer, Mars B. & Tjønnfjord, Geir Erland [Show all 20 contributors for this article] (2017). Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia. Leukemia and Lymphoma. ISSN 1042-8194. 58(10), p. 2356–2362. doi: 10.1080/10428194.2017.1285027.
• Vojdeman, Fie Juhl; van't Veer, Mars B.; Tjønnfjord, Geir Erland; Itälä-Remes, Maija; Kimby, Eva & Polliack, Aaron [Show all 15 contributors for this article] (2017). The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia. Leukemia and Lymphoma. ISSN 1042-8194. 58(3), p. 594–600. doi: 10.1080/10428194.2016.1213831.
• Stray-Pedersen, Asbjørg; Sorte, Hanne Sørmo; Samarakoon, Pubudu Saneth; Gambin, Tomasz; Chinn, Ivan K. & Akdemir, Zeynep H.C. [Show all 51 contributors for this article] (2016). Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. Journal of Allergy and Clinical Immunology. ISSN 0091-6749. 139(1), p. 232–245. doi: 10.1016/j.jaci.2016.05.042.
• Fløisand, Yngvar; Lundin, Knut Erik Aslaksen; Lazarevic, Vladimir; Kristiansen, Jørn Dehli; Osnes, Liv T. N. & Tjønnfjord, Geir Erland [Show all 8 contributors for this article] (2016). Targeting integrin α4β7 in steroid-refractory intestinal graft-versus-host disease. Biology of Blood and Marrow Transplantation. ISSN 1083-8791. 23(1), p. 172–175. doi: 10.1016/j.bbmt.2016.10.009.
• Barratt-Due, Andreas; Fløisand, Yngvar; Lang, Hilde Elisabeth; Kvam, Ann Kristin; Holme, Pål Andre & Bergseth, Grete [Show all 8 contributors for this article] (2016). Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology. ISSN 1462-0324. doi: 10.1093/rheumatology/kew040. Full text in Research Archive
• Vandraas, Kathrine; Tjønnfjord, Geir Erland; Johannessen, Tom Børge & Brandal, Petter (2016). Persistent bone marrow depression following short-term treatment with temozolomide. BMJ Case Reports. ISSN 1757-790X. 2016. doi: 10.1136/bcr-2016-215797.
• Lenartova, Andrea; Johannessen, Tom Børge & Tjønnfjord, Geir Erland (2016). National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953–2012: a systematic analysis of population-based data. Cancer Medicine. ISSN 2045-7634. 5(12), p. 3588–3595. doi: 10.1002/cam4.849. Full text in Research Archive Show summary

  Chronic lymphocytic leukemia is a disease of the elderly, and despite major advances in treatment, remains incurable. The Cancer Registry of Norway has registered data on patients with chronic lymphocytic leukemia since 1953. We aimed to analyze trends in incidence and survival of chronic lymphocytic leukemia in Norway. We identified 7664 patients reported with chronic lymphocytic leukemia to the registry between 1953 and 2012. We gathered information on sex, age at diagnosis, date of death and basis for diagnosis. The age-standardized incidence increased from 0.6/100.000 person-years in 1953 to 3.1/100,000 person-years in 2012. We found a significant decrease in median age between 1993–2002 and 2003–2012 (75 vs. 72 years, 95%CI: 2.52–3.98, P < 0.001). Men were diagnosed at a significantly younger age than women. Immunophenotyping has become the most important diagnostic method after 2002. Median observed survival increased from 3 years in 1952–1963 to 8.5 years in 2003–2012. Five- and 10-year age-standardized net survival increased throughout the whole period across age groups and reached 79% and 57%, respectively. Median observed survival was significantly shorter in men than in women in 1993–2002 (4.9 vs. 6.1 years, P < 0.001). The gap between survival rates for men and women was diminishing in 2003–2012 in patients younger than 60 years while it remained considerable in older patients. Despite an aging Norwegian population, chronic lymphocytic leukemia (CLL) patients become younger at diagnosis. A fourfold increase in incidence, a prolonged survival, and major changes in diagnostic methods in Norway were observed.

• von Krogh, Anne-Sophie; Quist-Paulsen, Petter; Waage, Anders; Langseth, Øystein Olstad; Thorstensen, Ketil & Brudevold, Robert [Show all 10 contributors for this article] (2016). High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: From clinical observation to evidence. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 14(1), p. 73–82. doi: 10.1111/jth.13186.
• Lappegård, Knut Tore; Bjerre, Anna Kristina; Tjønnfjord, Geir Erland & Mollnes, Tom Eirik (2015). Terapeutisk komplementhemming – fra eksperimentell til klinisk medisin. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 135(19), p. 1745–1749. doi: 10.4045/tidsskr.15.0049.
• Nissen-Meyer, Lise Sofie Haug; Tjønnfjord, Geir Erland; Golebiowska, Elzbieta; Kjeldsen-Kragh, Jens & Akkøk, Cigdem Ahaein (2015). Paroksysmal nattlig hemoglobinuri ved Oslo universitetssykehus 2000-10 :. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 135(11), p. 1039–1043. doi: 10.4045/tidsskr.14.0444.
• Torkildsen, Synne; Gorunova, Ludmila; Beiske, Klaus; Tjønnfjord, Geir Erland; Heim, Sverre & Panagopoulos, Ioannis (2015). Novel ZEB2-BCL11B fusion gene identified by RNA-sequencing in acute myeloid leukemia with t(2;14)(q22;q32). PLOS ONE. ISSN 1932-6203. 10(7). doi: 10.1371/journal.pone.0132736.
• Berentsen, Sigbjørn; Randen, Ulla & Tjønnfjord, Geir Erland (2015). Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America. ISSN 0889-8588. 29(3), p. 455–471. doi: 10.1016/j.hoc.2015.01.002.
• Ghanima, Waleed Khalid; Khelif, Abderrahim; Waage, Anders; Michel, Marc; Tjønnfjord, Geir Erland & Romdhan, Neila Ben [Show all 9 contributors for this article] (2015). Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): A multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. ISSN 0140-6736. 385(9978), p. 1653–1661. doi: 10.1016/S0140-6736(14)61495-1.
• Bürgler, Simone; Vives, Aleix Gimeno; Ribes, Anna Maria Parente; Wang, Dong; Os, Audun & Devereux, Stephen [Show all 10 contributors for this article] (2015). Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism. Journal of Immunology. ISSN 0022-1767. 194(2), p. 827–835. doi: 10.4049/jimmunol.1401350.
• Tran, Hoa Thi Tuyet; Sørensen, B.; Bjørnsen, Stine; Pripp, Are Hugo; Tjønnfjord, Geir Erland & Holme, Pål Andre (2015). Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay. Haemophilia. ISSN 1351-8216. 21(2), p. 275–283. doi: 10.1111/hae.12570.
• Tangen, Jon-Magnus; Tierens, Anne; Caers, Jo; Binsfeld, Marilene; Olstad, Ole Kristoffer & Siebke, Anne-Marie [Show all 9 contributors for this article] (2015). Immunomodulatory Effects of the Agaricus blazei Murrill-Based Mushroom Extract AndoSan in Patients with Multiple Myeloma Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation: A Randomized, Double Blinded Clinical Study. BioMed Research International. ISSN 2314-6133. doi: 10.1155/2015/718539.
• Awan, Haneef; Furuholmen, Johanna; Tjønnfjord, Geir Erland; Ly, Bernt; Johannesen, Tom Børge & Tierens, Anne [Show all 8 contributors for this article] (2014). Segregation of Malignant Hematological Disease in Families with Malignant Lymphoma. Journal of genetic syndrome & gene therapy. ISSN 2157-7412. 5(6).
• Jønsson, Viggo; Awan, Haneef; Johannesen, Tom Børge & Tjønnfjord, Geir Erland (2014). Chronic Lymphocytic Leukemia, Advantages of Monoclones? Journal of Leukemia. ISSN 2329-6917. 2(3).

View all works in Cristin

• Kreyberg, Ina; Schrumpf, Elisabeth; von Krogh, Carl Fredrik; Lilleng, Rune & Tjønnfjord, Geir Erland (2023). Successful treatment of subcorneal pustular dermatosis targeting an underlying monoclonal IgA gammopathy. Journal of the American Academy of Dermatology Case Reports. 41, p. 33–36. doi: 10.1016/j.jdcr.2023.08.036. Full text in Research Archive
• Tjønnfjord, Sara Kristina Viberg; Ali, Maryan Mohamed & Tjønnfjord, Geir Erland (2023). Kronisk nøytropeni hos voksne. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(9). doi: 10.4045/tidsskr.22.0491.
• Malecka, Agnieszka Maria; Østlie, Ingunn; Trøen, Gunhild; Malecki, Jedrzej Mieczyslaw; Delabie, Jan & Tierens, Anne [Show all 8 contributors for this article] (2022). Gene Expression Analysis Reveals Downregulation of Complement Receptor 1 in Cold Agglutinin Disease. Blood. ISSN 0006-4971. 140(1), p. 6419–6420. doi: 10.1182/blood-2022-156489.
• Cui, Xueyan; Myklebust, June Helen; Munthe, Ludvig A; Schjesvold, Fredrik Hellem; Tjønnfjord, Geir Erland & Stavik, Benedicte [Show all 7 contributors for this article] (2022). Single-cell sequencing reveals procoagulant microenvironment in precursor stages of multiple myeloma .
• Cui, Xueyan; Myklebust, June Helen; Munthe, Ludvig A.; Schjesvold, Fredrik Hellem; Tjønnfjord, Geir Erland & Sandset, Per Morten [Show all 7 contributors for this article] (2022). Low expression of coagulation inhibitors in the immune microenvironment in precursor stages of multiple myeloma. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379.
• Tasken, Kjetil; Russnes, Hege Elisabeth Giercksky; Aas, Eline; Bjørge, Line; Blix, Egil Støre & Ahlquist, Terje C. [Show all 116 contributors for this article] (2022). A national precision cancer medicine implementation initiative for Norway. Nature Medicine. ISSN 1078-8956. 28(5), p. 885–887. doi: 10.1038/s41591-022-01777-4.
• Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne & Berg, Thomas [Show all 53 contributors for this article] (2022). Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway (Journal of Translational Medicine, (2022), 20, 1, (225), 10.1186/s12967-022-03432-5). Journal of Translational Medicine. ISSN 1479-5876. 20(1). doi: 10.1186/s12967-022-03518-0.
• Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne & Berg, Thomas [Show all 53 contributors for this article] (2022). Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. Journal of Translational Medicine. ISSN 1479-5876. 20(1), p. 1–11. doi: 10.1186/s12967-022-03432-5. Full text in Research Archive Show summary

  Background Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen due to recent advancements in cancer diagnostics including access to high-throughput sequencing of tumour tissue. Targeted therapies interfering with cancer specific pathways have been developed and approved for subgroups of patients. These drugs might just as well be efficient in other diagnostic subgroups, not investigated in pharma-led clinical studies, but their potential use on new indications is never explored due to limited number of patients. Methods In this national, investigator-initiated, prospective, open-label, non-randomized combined basket- and umbrella-trial, patients are enrolled in multiple parallel cohorts. Each cohort is defined by the patient’s tumour type, molecular profile of the tumour, and study drug. Treatment outcome in each cohort is monitored by using a Simon two-stage-like ‘admissible’ monitoring plan to identify evidence of clinical activity. All drugs available in IMPRESS-Norway have regulatory approval and are funded by pharmaceutical companies. Molecular diagnostics are funded by the public health care system.

• Midtvedt, Øyvind; Stray-Pedersen, Asbjørg; Andersson, Anna Helena; Gunnarsson, Ragnar; Tveten, Kristian & Ali, Maryan Mohamed [Show all 7 contributors for this article] (2022). En mann i 6o-årene med kondritt og benmargssvikt. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 142(4). doi: 10.4045/tidsskr.21.0370. Full text in Research Archive
• Tvedt, Tor Henrik Anderson; Steien, Egil; Øvrebø, Bente; Haaverstad, Rune; Hobbs, William & Wardęcki, Marek [Show all 8 contributors for this article] (2022). Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery. American Journal of Hematology. ISSN 0361-8609. 97(2), p. E51–E54. doi: 10.1002/ajh.26409.
• Tjønnfjord, Sara Kristina Viberg; Tjønnfjord, Eirik; Konopski, Zbigniew & Tjønnfjord, Geir Erland (2021). Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia. Case Reports in Hematology. ISSN 2090-6560. 2021:1862446, p. 1–4. doi: 10.1155/2021/1862446. Full text in Research Archive
• Malecka, Agnieszka Maria; Trøen, Gunhild; Delabie, Jan; Malecki, Jedrzej Mieczyslaw; Østlie, Ingunn & Tierens, Anne [Show all 9 contributors for this article] (2021). The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels. American Journal of Hematology. ISSN 0361-8609. doi: 10.1002/ajh.26205.
• Malecka, Agnieszka Maria; Delabie, Jan; Østlie, Ingunn; Tierens, Anne; Randen, Ulla & Berentsen, Sigbjørn [Show all 8 contributors for this article] (2020). Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18. Blood Advances. ISSN 2473-9529. 4(6), p. 993–996. doi: 10.1182/bloodadvances.2020001608.
• Cui, Xueyan; Tjønnfjord, Geir Erland; Kanse, Sandip; Iversen, Nina; Dahm, Anders Erik A & Myklebust, Christiane Filion [Show all 11 contributors for this article] (2019). Tissue factor pathway inhibitor enhances transendothelial migration of chronic lymphocytic leukemia cells trhough CXCL12/CXCR7 chemotaxis. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 3.
• Diep, Phoi Phoi; Melberg, Hans Olav; Brinch, Lorentz; Buechner, Jochen; Fløisand, Yngvar & Gedde-Dahl, Thobias [Show all 9 contributors for this article] (2018). Cost-utility of allogeneic hematopoietic stem cell transplantation in Norway. Bone Marrow Transplantation. ISSN 0268-3369. 53(5), p. 657–660. doi: 10.1038/s41409-018-0091-y.
• Diep, Phoi Phoi; Melberg, Hans Olav; Brinch, Lorentz; Buechner, Jochen; Fløisand, Yngvar & Gedde-Dahl, Thobias [Show all 8 contributors for this article] (2017). Allogeneic hematopoietic stem cell transplantation in Norway 1974-2009: Cost-utility and survival in children and young adults .
• Malecka, Agnieszka Maria; Trøen, Gunhild; Tierens, Anne; Østlie, Ingunn; Malecki, Jedrzej Mieczyslaw & Randen, Ulla [Show all 9 contributors for this article] (2016). Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity. Haematologica. ISSN 0390-6078. 101(9), p. e361–e364. doi: 10.3324/haematol.2016.146126.
• Ribes, Anna Maria Parente; Skånland, Sigrid Strand; Bürgler, Simone; Os, Audun; Wang, Dong & Bogen, Bjarne [Show all 9 contributors for this article] (2016). Spleen tyrosine kinase inhibitors reduce CD40l-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells. Haematologica. ISSN 0390-6078. 101(2), p. e59–e62. doi: 10.3324/haematol.2015.135590.
• Tjønnfjord, Geir Erland & Bogen, Bjarne (2015). Myeloproliferative og lymfoproliferative sykdommer. In Hagve, Tor-Arne & Berg, Jens Petter (Ed.), Klinisk biokjemi og fysiologi. Gyldendal Akademisk. ISSN 978-82-05-46367-7. p. 140–154.

View all works in Cristin